The most profitable drug known to man. Liquid goldThe title speaks for itself self.
Weekly RSI retesting a 10yr low.
Ozempic (GLP1) is and will continue to be the most profitable drug known to man.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.146 EUR
13.50 B EUR
38.82 B EUR
3.16 B
About NOVO NORDISK B A/S
Sector
Industry
CEO
Lars Fruergaard Jørgensen
Website
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG000RYSN40
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
nvo bullish long Long Setup Idea – Not Financial Advice - AH
This is a long trade setup based on my personal analysis.
The entry, stop-loss, and target levels are outlined for educational and illustrative purposes only.
📈 Entry:
🛑 Stop Loss:
🎯 Target(s):
Disclaimer:
I am not a financial advisor. This idea i
NVO Exhibits High Monthly Volume Amid Downtrend – SHortNVO Exhibits High Monthly Volume Amid Downtrend – Potential Accumulation Phase
📉 Post:
Novo Nordisk (NVO) has experienced a significant decline from its 52-week high of $148.15 to a recent low of $57.00. However, the monthly chart reveals an unusually high trading volume, which may indicate accumul
NVO bounce off of Ozempic launch AVWAPOzempic launched Feb 5 2018. Anchoring our VWAP to that date we get our confirmation of a strong anchor from the COVID bounce, indicating institutional buying at that level. Over 7 years later, we get another opportunity.
Novo 1h longShould get up and at least break the neckline from the bigger SHS/IHS.
Stop below zone or lower trendline.
NVO buyThis downturn has been influenced by several factors:
Leadership Changes: CEO Lars Fruergaard Jørgensen is stepping down after eight years, following a sharp decline in the company's stock price.
STAT
+8
MarketWatch
+8
WSJ
+8
Increased Competition: Eli Lilly's weight-loss drugs, Mounjaro and Zepb
NOV - CONTINUATION OF A DOWNTREND OR START OF A NEWGood Morning,
Hope all is well. NVO has been in a down trend since Feb 26 2025, like most stocks. NVO tried to move past the 70$ price point however it was rejected and is now seeking lower support. Currently for trend there is an ascending channel. A break above the mid-line is bullish, a failure
NVO entering a great buying zoneNOVO has entered into the golden retracement for and good buying zone.
Looking to buy between 62.50 and 60.
Sell targets $90, 110 and 135.
Novo Nordisk Stock Chart Fibonacci Analysis 050925Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 411/61.80%
Chart time frame: D
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress: A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) 61.80% support
D) Hit the bottom
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOV is featured.
Related stocks
Frequently Asked Questions
The current price of NOV is 62.460 EUR — it has decreased by −1.75% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TRADEGATE exchange NOVO NORDISK A/S stocks are traded under the ticker NOV.
NOV stock has risen by 1.94% compared to the previous week, the month change is a 5.38% rise, over the last year NOVO NORDISK A/S has showed a −49.79% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOV price has a max estimate of 120.28 EUR and a min estimate of 46.78 EUR. Watch NOV chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOV stock is 3.06% volatile and has beta coefficient of 1.41. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of 282.09 B, it has increased by 2.43% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.87 EUR per share, whereas the estimation was 0.82 EUR resulting in a 6.95% surprise. The estimated earnings for the next quarter are 0.80 EUR per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to 10.46 B EUR, despite the estimated figure of 10.44 B EUR. In the next quarter, revenue is expected to reach 10.40 B EUR.
NOV net income for the last quarter is 3.89 B EUR, while the quarter before that showed 3.77 B EUR of net income which accounts for 3.03% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Jun 4, 2025, the company has 76.3 K employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is 21.00 B EUR, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.